


**Amendments to the Claims**

Please cancel Claims 12 and 14-17. Please add new Claims 21-63. The Claim Listing below will replace all prior versions of the claims in the application:


**Claim Listing**

1. (Original) A compound having the formula:



- or a physiologically acceptable salt thereof, wherein R<sup>1</sup> is a halogen.
2. (Original) The compound of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of chloro, fluoro and bromo.
3. (Original) The compound of Claim 2 wherein R<sup>1</sup> is chloro.
4. (Original) A pharmaceutical composition comprising the compound of Claim 1 and a physiologically acceptable carrier or excipient.
5. (Original) A method for treating a disease characterized by pathogenic leukocyte recruitment, pathogenic leukocyte activation or pathogenic leukocyte recruitment and activation, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.


6. (Original) A compound having the structure:



or a physiologically acceptable salt thereof, wherein R<sup>1</sup> is a halogen.

7. (Original) The compound of Claim 6 wherein R<sup>1</sup> is selected from the group consisting of chloro, fluoro and bromo.
8. (Original) The compound of Claim 7 wherein R<sup>1</sup> is chloro.
9. (Original) A pharmaceutical composition comprising the compound of Claim 6 and a physiologically acceptable carrier or excipient.
10. (Original) A method for treating a disease characterized by pathogenic leukocyte recruitment, pathogenic leukocyte activation or pathogenic leukocyte recruitment and activation, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
11. (Original) The method of Claim 10 wherein R<sup>1</sup> chloro.

12. (Canceled)
13. (Original) The method of Claim 10 wherein said disease is selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma.
- 14-17. (Canceled)
18. (Original) A method of antagonizing a C-C Chemokine Receptor 1 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
19. (Original) A compound having the formula:



or a physiologically acceptable salt thereof, wherein R<sup>1</sup> is a halogen.

20. (Original) A pharmaceutical composition comprising the compound of Claim 19 and a physiologically acceptable carrier or excipient.
21. (New) The compound of Claim 19 wherein R<sup>1</sup> is selected from the group consisting of chloro, fluoro and bromo.
22. (New) The compound of Claim 21 wherein R<sup>1</sup> is chloro.
23. (New) A method for treating a disease characterized by pathogenic leukocyte recruitment, pathogenic leukocyte activation or pathogenic leukocyte recruitment and activation, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
24. (New) The method of Claim 23 wherein said disease is selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma.
25. (New) The method of Claim 5 wherein said disease is selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma.
26. (New) A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
27. (New) The method of Claim 24, wherein said inflammatory disease is an acute inflammatory disease.

28. (New) The method of Claim 24, wherein said inflammatory disease is a chronic inflammatory disease.
29. (New) A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
30. (New) The method of Claim 27, wherein said inflammatory disease is an acute inflammatory disease.
31. (New) The method of Claim 27, wherein said inflammatory disease is a chronic inflammatory disease.
32. (New) A method for treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
33. (New) The method of Claim 30 wherein said inflammatory disease is an acute inflammatory disease.
34. (New) The method of Claim 30 wherein said inflammatory disease is a chronic inflammatory disease.
35. (New) A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
36. (New) The method of Claim 33 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter's syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.

37. (New) A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
38. (New) The method of Claim 35 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter's syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
39. (New) A method for treating inflammatory arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
40. (New) The method of Claim 37 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, Reiter's syndrome, psoriatic arthritis, psoriatic spondylitis, enteropathic arthritis, enteropathic spondylitis, juvenile-onset spondyloarthropathy and undifferentiated spondyloarthropathy.
41. (New) A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
42. (New) The method of Claim 39 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
43. (New) The method of Claim 40 wherein said acute demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
44. (New) The method of Claim 39 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.

45. (New) The method of Claim 42 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
46. (New) A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
47. (New) The method of Claim 44 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
48. (New) The method of Claim 45 wherein said acute demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.
49. (New) The method of Claim 44 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
50. (New) The method of Claim 47 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
51. (New) A method for treating inflammatory demyelinating disease, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
52. (New) The method of Claim 49 wherein said inflammatory demyelinating disease is acute inflammatory demyelinating disease.
53. (New) The method of Claim 50 wherein said acute demyelinating disease is selected from the group consisting of acute disseminated encephalomyelitis, Guillain-Barre syndrome and acute hemorrhagic leukoencephalitis.

54. (New) The method of Claim 49 wherein said inflammatory demyelinating disease is chronic inflammatory demyelinating disease.
55. (New) The method of Claim 52 wherein said chronic inflammatory demyelinating disease is multiple sclerosis or chronic inflammatory demyelinating polyradiculoneuropathy.
56. (New) A method of antagonizing a C-C Chemokine Receptor 1 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
57. (New) A method of antagonizing a C-C Chemokine Receptor 1 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
58. (New) A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
59. (New) A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
60. (New) A method for treating rheumatoid arthritis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.
61. (New) A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.
62. (New) A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 6.
63. (New) A method for treating multiple sclerosis, comprising administering to a subject in need thereof an effective amount of a compound of Claim 19.